Newly finalized FDA guidance is intended to explain how the agency uses various methods in advance of or in lieu of inspections to assess the manufacturing facilities of firms that have submitted marketing applications for drugs and biologics. The guidance, “Alternative Tools: Assessing Drug Manufacturing Facilities Identified in Pending Applications,” incorporates best pract... Read More